Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Free Cash Flow data on file, last reported at -$12.6 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 25.53% year-over-year to -$12.6 million in Q1 2026; TTM through Mar 2026 was -$77.6 million, a 68.46% decrease from a year earlier, with the FY2025 full-year figure at -$82.0 million, down 85.47% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$12.6 million, up from -$27.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for JANX reached as high as -$2.0 million in Q3 2024 and fell as low as -$27.3 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$13.8 million across 5 years, with a median of -$12.6 million in 2026.
• Across the five-year window, Free Cash Flow surged 83.49% in 2024 and slumped 553.66% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$12.2 million in 2022, then gained by 14.8% to -$10.4 million in 2023, then plunged by 63.77% to -$17.1 million in 2024, then slumped by 60.21% to -$27.3 million in 2025, then jumped by 53.86% to -$12.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$12.6 million in Q1 2026, -$27.3 million in Q4 2025, and -$12.9 million in Q3 2025.